C

ChoA Pharmaceutical Co Ltd
KOSDAQ:034940

Watchlist Manager
ChoA Pharmaceutical Co Ltd
KOSDAQ:034940
Watchlist
Price: 991 KRW -2.75% Market Closed
Market Cap: 30.7B KRW

Relative Value

The Relative Value of one ChoA Pharmaceutical Co Ltd stock under the Base Case scenario is hidden KRW. Compared to the current market price of 991 KRW, ChoA Pharmaceutical Co Ltd is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ChoA Pharmaceutical Co Ltd Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
87
vs Industry
83
Median 3Y
0.8
Median 5Y
1
Industry
2.6
vs History
vs Industry
18
Median 3Y
-3.2
Median 5Y
-4.7
Industry
21.4
vs History
vs Industry
Median 3Y
-13.1
Median 5Y
-22.5
Industry
16.4
vs History
vs Industry
Median 3Y
-15.5
Median 5Y
-19
Industry
22.8
vs History
88
vs Industry
61
Median 3Y
1.2
Median 5Y
1.3
Industry
2.2
vs History
87
vs Industry
77
Median 3Y
1
Median 5Y
1.2
Industry
2.9
vs History
88
vs Industry
66
Median 3Y
2.8
Median 5Y
3
Industry
5.5
vs History
vs Industry
17
Median 3Y
-6.9
Median 5Y
-10.7
Industry
13
vs History
vs Industry
3
Median 3Y
-5.3
Median 5Y
-10.7
Industry
16.5
vs History
vs Industry
Median 3Y
-17.5
Median 5Y
-28.3
Industry
15.6
vs History
vs Industry
Median 3Y
-14.6
Median 5Y
-18.8
Industry
18.7
vs History
88
vs Industry
64
Median 3Y
1
Median 5Y
1.1
Industry
1.9

Multiples Across Competitors

Competitors Multiples
ChoA Pharmaceutical Co Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
KR
ChoA Pharmaceutical Co Ltd
KOSDAQ:034940
30.7B KRW 0.5 -3 -6.4 -5
US
Eli Lilly and Co
NYSE:LLY
1T USD 17.3 55.7 37.4 40.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
495.1B USD 5.4 19.7 16.1 20.9
CH
Roche Holding AG
SIX:ROG
270.3B CHF 4.4 28.7 12.2 14.2
UK
AstraZeneca PLC
LSE:AZN
219.8B GBP 5.1 31.4 108.8 159.2
US
Merck & Co Inc
NYSE:MRK
276.1B USD 4.3 14.5 10.3 12.2
CH
Novartis AG
SIX:NOVN
218.3B CHF 4.9 19 12 15.5
DK
Novo Nordisk A/S
CSE:NOVO B
1.6T DKK 5.2 15.8 11 12.8
IE
Endo International PLC
LSE:0Y5F
213.9B USD 92.2 -73.2 338.7 849.2
US
Pfizer Inc
NYSE:PFE
143.8B USD 2.3 14.6 7.5 10.2
P/E Multiple
Earnings Growth PEG
KR
C
ChoA Pharmaceutical Co Ltd
KOSDAQ:034940
Average P/E: 24.9
Negative Multiple: -3
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
55.7
54%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.7
29%
0.7
CH
Roche Holding AG
SIX:ROG
28.7
29%
1
UK
AstraZeneca PLC
LSE:AZN
31.4
37%
0.8
US
Merck & Co Inc
NYSE:MRK
14.5
15%
1
CH
Novartis AG
SIX:NOVN
19
17%
1.1
DK
Novo Nordisk A/S
CSE:NOVO B
15.8
3%
5.3
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -73.2 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.6
27%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
KR
C
ChoA Pharmaceutical Co Ltd
KOSDAQ:034940
Average EV/EBITDA: 440
Negative Multiple: -6.4
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
37.4
34%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.1
9%
1.8
CH
Roche Holding AG
SIX:ROG
12.2
5%
2.4
UK
AstraZeneca PLC
LSE:AZN
108.8
10%
10.9
US
Merck & Co Inc
NYSE:MRK
10.3
6%
1.7
CH
Novartis AG
SIX:NOVN
12
6%
2
DK
Novo Nordisk A/S
CSE:NOVO B
11
1%
11
IE
E
Endo International PLC
LSE:0Y5F
338.7
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.5
0%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
KR
C
ChoA Pharmaceutical Co Ltd
KOSDAQ:034940
Average EV/EBIT: 1 883.7
Negative Multiple: -5
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
40.1
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
20.9
15%
1.4
CH
Roche Holding AG
SIX:ROG
14.2
6%
2.4
UK
AstraZeneca PLC
LSE:AZN
159.2
23%
6.9
US
Merck & Co Inc
NYSE:MRK
12.2
8%
1.5
CH
Novartis AG
SIX:NOVN
15.5
12%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
12.8
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
849.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.2
7%
1.5